A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients

E. Cassinerio; A. Roghi; N. Orofino; P. Pedrotti; L. Zanaboni; E. Poggiali; M. Giuditta; D. Consonni; M. D. Cappellini

doi:10.1007/s00277-014-2291-x

A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients

E. Cassinerio, A. Roghi, N. Orofino, P. Pedrotti, L. Zanaboni, E. Poggiali, M. Giuditta, D. Consonni, M. D. Cappellini

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Deferasirox (DFX) is an oral iron chelator with established efficacy and safety. We evaluated by T2* cardiovascular magnetic resonance (CMR) the efficacy of DFX in preventing and removing cardiac and liver iron load and cardiac volume changes, along 5 years in adult thalassemia major (TM) patients. Twenty-three TM patients (9 males/14 women, mean age 36 ± 4 years) were included in this study. Repeated CMR was performed to assess myocardial and liver iron load (baseline t0, after 2.5 years t1, after 5 years t2). Myocardial T2* values changed progressively and increased significantly between t0 and t2 (t0: 27.15 ± 9.58 vs t2: 36.64 ± 6.68, p = 0.0001). At baseline evaluation, a cardiac T2* value

Original language	English
Pages (from-to)	939-945
Number of pages	7
Journal	Annals of Hematology
Volume	94
Issue number	6
DOIs	https://doi.org/10.1007/s00277-014-2291-x
Publication status	Published - Jun 1 2015

Keywords

Cardiac iron overload
Chelation therapy
Deferasirox
Liver iron overload
Thalassemia major

ASJC Scopus subject areas

Hematology
Medicine(all)

Access to Document

10.1007/s00277-014-2291-x

Cite this

Cassinerio, E., Roghi, A., Orofino, N., Pedrotti, P., Zanaboni, L., Poggiali, E., Giuditta, M., Consonni, D., & Cappellini, M. D. (2015). A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients. Annals of Hematology, 94(6), 939-945. https://doi.org/10.1007/s00277-014-2291-x

A 5-year follow-up in deferasirox treatment : improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients. / Cassinerio, E.; Roghi, A.; Orofino, N.; Pedrotti, P.; Zanaboni, L.; Poggiali, E.; Giuditta, M.; Consonni, D.; Cappellini, M. D.

In: Annals of Hematology, Vol. 94, No. 6, 01.06.2015, p. 939-945.

Research output: Contribution to journal › Article › peer-review

Cassinerio, E, Roghi, A, Orofino, N, Pedrotti, P, Zanaboni, L, Poggiali, E, Giuditta, M, Consonni, D & Cappellini, MD 2015, 'A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients', Annals of Hematology, vol. 94, no. 6, pp. 939-945. https://doi.org/10.1007/s00277-014-2291-x

@article{d23f032376ab4a1cafcda25aaa5a82ea,

title = "A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients",

abstract = "Deferasirox (DFX) is an oral iron chelator with established efficacy and safety. We evaluated by T2* cardiovascular magnetic resonance (CMR) the efficacy of DFX in preventing and removing cardiac and liver iron load and cardiac volume changes, along 5 years in adult thalassemia major (TM) patients. Twenty-three TM patients (9 males/14 women, mean age 36 ± 4 years) were included in this study. Repeated CMR was performed to assess myocardial and liver iron load (baseline t0, after 2.5 years t1, after 5 years t2). Myocardial T2* values changed progressively and increased significantly between t0 and t2 (t0: 27.15 ± 9.58 vs t2: 36.64 ± 6.68, p = 0.0001). At baseline evaluation, a cardiac T2* value ",

keywords = "Cardiac iron overload, Chelation therapy, Deferasirox, Liver iron overload, Thalassemia major",

author = "E. Cassinerio and A. Roghi and N. Orofino and P. Pedrotti and L. Zanaboni and E. Poggiali and M. Giuditta and D. Consonni and Cappellini, {M. D.}",

year = "2015",

month = jun,

day = "1",

doi = "10.1007/s00277-014-2291-x",

language = "English",

volume = "94",

pages = "939--945",

journal = "Revue d'hématologie",

issn = "0939-5555",

publisher = "Springer Verlag",

number = "6",

}

TY - JOUR

T1 - A 5-year follow-up in deferasirox treatment

T2 - improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients

AU - Cassinerio, E.

AU - Roghi, A.

AU - Orofino, N.

AU - Pedrotti, P.

AU - Zanaboni, L.

AU - Poggiali, E.

AU - Giuditta, M.

AU - Consonni, D.

AU - Cappellini, M. D.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Deferasirox (DFX) is an oral iron chelator with established efficacy and safety. We evaluated by T2* cardiovascular magnetic resonance (CMR) the efficacy of DFX in preventing and removing cardiac and liver iron load and cardiac volume changes, along 5 years in adult thalassemia major (TM) patients. Twenty-three TM patients (9 males/14 women, mean age 36 ± 4 years) were included in this study. Repeated CMR was performed to assess myocardial and liver iron load (baseline t0, after 2.5 years t1, after 5 years t2). Myocardial T2* values changed progressively and increased significantly between t0 and t2 (t0: 27.15 ± 9.58 vs t2: 36.64 ± 6.68, p = 0.0001). At baseline evaluation, a cardiac T2* value

AB - Deferasirox (DFX) is an oral iron chelator with established efficacy and safety. We evaluated by T2* cardiovascular magnetic resonance (CMR) the efficacy of DFX in preventing and removing cardiac and liver iron load and cardiac volume changes, along 5 years in adult thalassemia major (TM) patients. Twenty-three TM patients (9 males/14 women, mean age 36 ± 4 years) were included in this study. Repeated CMR was performed to assess myocardial and liver iron load (baseline t0, after 2.5 years t1, after 5 years t2). Myocardial T2* values changed progressively and increased significantly between t0 and t2 (t0: 27.15 ± 9.58 vs t2: 36.64 ± 6.68, p = 0.0001). At baseline evaluation, a cardiac T2* value

KW - Cardiac iron overload

KW - Chelation therapy

KW - Deferasirox

KW - Liver iron overload

KW - Thalassemia major

UR - http://www.scopus.com/inward/record.url?scp=84937511547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937511547&partnerID=8YFLogxK

U2 - 10.1007/s00277-014-2291-x

DO - 10.1007/s00277-014-2291-x

M3 - Article

C2 - 25563596

AN - SCOPUS:84937511547

VL - 94

SP - 939

EP - 945

JO - Revue d'hématologie

JF - Revue d'hématologie

SN - 0939-5555

IS - 6

ER -

A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this